I. In the Claims (Clean Sheet)

D1

2. A peptide consisting of 16 to 55 amino acid residues, comprising the amino acid sequence YKLVCYYTSWSQYREG (SEQ ID NO: 1).

D2

7. A pharmaceutical composition comprising a peptide according to claim 2, and a pharmaceutically acceptable carrier.

D3

11. A test kit for use in the detection of activated autoreactive T cells, comprising a peptide according to claim 2.

13. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising the amino acid sequence YKLVCYYTSWSQYREG (SEQ ID NO:1).

D4

14. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising the amino acid sequence YKLVCYYTSWSQYREG (SEQ ID NO:1).

15. A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one or more peptides containing 16 to 55 amino acid residues selected from the group consisting of the amino acid sequence LVCYYTSWS (SEQ ID NO:60) and a pharmaceutically acceptable carrier.

D5

16. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 13.

D5

17. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 14.

II. In the Claims (Marked Version)

Please cancel claims 3-5, 10, 12, and 18 without prejudice or disclaimer.

Please amend the Claims as follows:

2. A peptide consisting of 16 to 55 amino acid residues, comprising[at least one of] the amino acid sequence[s] YKLVCYYTSWSQYREG (SEQ ID NO: 1)[, YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTFIKSVPPFL (SEQ ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17), PPFLRTHGFDGLDLAW (SEQ ID NO: 18), HGFDGLDLAWLYPGRR (SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20), TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLDFISIMT (SEQ ID NO: 29), QHLDFISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPDRFS (SEQ IS NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), PASKLVMGIPTFGRSF (SEQ ID NO: 39, GTLAYYEICDFLRGAT (SEQ ID NO: 46), EICDFLRGATVHRTLG (SEQ ID NO: 47), RGATVHRTLGQQVPYA (SEQ ID NO: 48), VKSKVQYLKDRQLAGA (SEQ ID NO: 53), YLKDRQLAGAMVWALD (SEQ ID NO: 54), LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD (SEQ ID NO: 56) and DFQGSFCGQDLRFPLT (SEQ ID NO: 57)].

7. A pharmaceutical composition comprising [one or more] a peptide[s] according to claim 2, and a pharmaceutically acceptable carrier.

11. A test kit for use in the detection of activated autoreactive T cells, comprising [one or more] a peptide[s] according to claim 2.

13. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising[at least one of] the amino acid sequence[s] YKLVCYYTSWSQYREG (SEQ ID NO:1)[, YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), PNLKTLLSVGGWNFGS (SEQ ID NO:12), NTQSRRTFIKSVPPFL (SEQ ID NO:16), TFIKSVPPFLRTHGFD (SEQ ID NO:17), PPFLRTHGFDGLDLAW (SEQ ID NO:18), HGFDGLDLAWLYPGRR (SEQ ID NO:19), DLAWLYPGRRDKQHFT (SEQ ID NO:20), TIDSSYDIAKISQHLD (SEQ ID NO:28), DIAKISQHLDFISIMT (SEQ ID NO:29), QHLDFISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), PASKLVMGIPTFGRSF (SEQ ID NO:39), GTLAYYEICDFLRGAT (SEQ ID NO:46), EICDFLRGATVHRTLG (SEQ ID NO:47), RGATVHRTLGQQVPYA (SEQ ID NO:48), VKSKVQYLKDRQLAGA (SEQ ID NO:53), YLKDRQLAGAMVWALD (SEQ ID NO:54), LAGAMVWALDLDDFQG (SEQ ID NO:55), WALDLDDFQGSFCGQD (SEQ ID NO:56) or DFQGSFCGQDLRFPLT (SEQ ID NO:57)].

14. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising [at least one of] the amino acid sequence[s] YKLVCYYTSWSQYREG (SEQ ID NO:1)[, YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), QHLDFISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), YLKDRQLAGAMVWALD (SEQ ID NO:54) and LAGAMVWALDLDDFQG (SEQ ID NO:55)].

15. A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one

or more peptides containing 16 to 55 amino acid residues selected from the group consisting of [at least one of] the amino acid sequence[s] LVCYYTS[Y]WS (SEQ ID NO:60)[, FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), FIKSVPPFL (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YKLDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO:77) or LDLDDFQGS (SEQ ID NO:78),] and a pharmaceutically acceptable carrier.

16. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 13.

17. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 14.

III. Remarks

A. Non-elected Subject Matter

Applicants have amended claims 2, 3, 7, 11, and 13-14 to comply with the Examiner's request and cancel nonelected subject matter. Furthermore, claims 4-5, 10, 12, and 18 have been cancelled. The amendments and cancellation was not made for any